Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto Indication Expansion Efforts Show That Fewer Could Be More

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J and Bayer continue quest for acute coronary syndrome claim following three rejections by FDA; this time, Xarelto will be tested on top of only one antiplatelet drug instead of two.

Advertisement

Related Content

COMPASS Success Reinforces J&J/Bayer's Broad Labeling Strategy For Xarelto
Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto
FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
Xarelto Review Sparks Debate Over Feasibility Of A Three-Drug ACS Regimen
Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel